Tanaka Tomohito, Terai Yoshito, Ohmichi Masahide
Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.
Oncol Lett. 2019 Jan;17(1):1306-1312. doi: 10.3892/ol.2018.9713. Epub 2018 Nov 15.
Matrix metalloproteinase-9 (MMP9) has been recognized to be an important factor in cancer invasion and metastasis. In contrast, decorin has been revealed to inhibit primary tumor development. The aim of the present study was to investigate the function of MMP9 and decorin in cervical cancer. Three experiments were performed to analyze the function of MMP9 and decorin in the invasion of cervical cancer by: i) Analyzing the expression of MMP9 and decorin by immunohistochemistry in 100 cervical specimens; ii) determining the concentration of decorin by an enzyme-linked immunosorbent assay (ELISA) using the human squamous cervical cancer cell line CaSki and human endometrial stromal cell line CRL4003 and iii) evaluating the invasion ability of CaSki cells in a cervical invasion model by an invasion assay. Immunohistochemistry revealed that MMP9 was overexpressed in microinvasive carcinoma (100.0%) but was less strongly expressed in normal or pre-malignant squamous epithelium (0-41.9%). In contrast, the activity of decorin in stroma adjacent to neoplastic cells was lower in microinvasive carcinoma (9.1%) compared with in normal or pre-malignant lesions (74.2-100.0%). An ELISA revealed that MMP9 released from CaSki cells resolved the decorin released from CRL4003 cells. An invasion assay demonstrated that the invasive ability of CaSki cells was suppressed by an MMP inhibitor, and decorin was released from CRL4003 cells. These data suggested that decorin prevented the invasion of malignant cells in uterine cervical cancer; however, MMP9 promotes cell invasion by destroying decorin.
基质金属蛋白酶-9(MMP9)已被公认为是癌症侵袭和转移的一个重要因素。相比之下,核心蛋白聚糖已被发现可抑制原发性肿瘤的发展。本研究的目的是探讨MMP9和核心蛋白聚糖在宫颈癌中的作用。进行了三项实验来分析MMP9和核心蛋白聚糖在宫颈癌侵袭中的作用:i)通过免疫组织化学分析100例宫颈标本中MMP9和核心蛋白聚糖的表达;ii)使用人宫颈鳞状癌细胞系CaSki和人子宫内膜基质细胞系CRL4003,通过酶联免疫吸附测定(ELISA)确定核心蛋白聚糖的浓度;iii)通过侵袭试验在宫颈癌侵袭模型中评估CaSki细胞的侵袭能力。免疫组织化学显示,MMP9在微浸润癌中过度表达(100.0%),但在正常或癌前鳞状上皮中表达较弱(0-41.9%)。相比之下,微浸润癌中肿瘤细胞邻近基质中核心蛋白聚糖的活性(9.1%)低于正常或癌前病变(74.2-100.0%)。ELISA显示,CaSki细胞释放的MMP9可分解CRL4003细胞释放的核心蛋白聚糖。侵袭试验表明,MMP抑制剂可抑制CaSki细胞的侵袭能力,且CRL4003细胞可释放核心蛋白聚糖。这些数据表明,核心蛋白聚糖可阻止子宫颈癌中恶性细胞的侵袭;然而,MMP9通过破坏核心蛋白聚糖促进细胞侵袭。